Acalabrutinib-Venetoclax With or Without Obinutuzumab Significantly Prolongs PFS in Fit Patients with Previously Untreated CLL By Ogkologos - February 25, 2025 872 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the AMPLIFY study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Strengthens Global Oncology Collaboration Through its Growing Presence in the Asia-Pacific Pemigatinib Prolongs mPFS Over Chemotherapy in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements FDA Approves Atezolizumab for Adjuvant Treatment of Muscle Invasive Bladder Cancer in Patients with Molecular Residual Disease MOST POPULAR Study Finds Accelerated Partial-Breast Radiation Just as Effective as Whole Breast... December 13, 2019 Majority of Patients With Cancer Are Willing To Be Vaccinated Against... February 2, 2021 Tecartus Becomes First CAR T-Cell Therapy Approved for Adults with ALL November 10, 2021 An Updated Overview of Estimates for Cancer Incidence and Mortality in... June 23, 2022 Load more HOT NEWS EMA Recommends Extension of Indications for Tafasitamab ESMO Strengthens Global Oncology Collaboration Through its Growing Presence in the... Woman Diagnosed with Cancer a Week After Her Honeymoon Helps Others... AI-Supported Mammography Screening Shows Favourable Outcomes Compared with Standard Double Reading
